Antiangiogenic effects of S-nitrosocaptopril crystals as a nitric oxide donor

European Journal of Pharmacology

Volumn 391, Issue 1-2, 2000, Pages 137-144

  Jia, Lee ^a   Wu, Chi Cheng ^b   Guo, Wenhu ^c   Young, Xinping ^c  

^a La Jolla Pharmaceutical Company   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Angiogenesis; Capillary endothelium; Captopril; Chick embryo; Chorioallantoic membrane; Hemoglobin; Nitric oxide (NO); S nitrosocaptopril

Indexed keywords

CAPTOPRIL; GELATIN SPONGE; NITRIC OXIDE; S NITROSOCAPTOPRIL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIUM; CELL MIGRATION; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPILLARIES; CAPTOPRIL; CELL DIVISION; CHICK EMBRYO; CHORION; CRYSTALLIZATION; ENDOTHELIUM, VASCULAR; HEMOGLOBINS; MALE; MEMBRANES; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE DONORS; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ULTRAVIOLET; X-RAY DIFFRACTION;

EID: 0034629463     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00794-3     Document Type: Article

References (32)

1. Amano M., Takahashi M., Kosaka T., Kinoshita M. Differential inhibition of platelet aggregation and calcium mobilization by nitroglycerin and stabilized nitric oxide. J. Cardiovasc. Pharmacol. 24:1994;860-866.
2. Assendelft O.W.V. Spectrophotometry of haemoglobin derivatives. 1st:1970;Royal VanGorcum, The Netherlands.
3. Clancy R.M., Levartovsky D., Leszczy-Piziak J., Yegudin J., Abramson S.B. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3680-3684.
4. Cooke J.P., Andon N., Loscalzo J. S-nitrosocaptopril: II. Effects on vascular reactivity. J. Pharmacol. Exp. Ther. 249:1989;730-734.
5. Fernandez L.A., Twickler J., Mead A. Neovascularization produced by angiotensin II. Lab. Clin. Med. 105:1985;141-145.
6. Ferrara N., Davis-Smith T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-24.
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1:1995;27-31.
8. Folkman J., Haudenschild C.C., Zetter B.R. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 76:1979;5217-5221.
9. Furchgott R.F. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor (EDRF) is nitric oxide. Vanhoutte P.M. Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium. 1988;401-414 Raven, New York.
10. Granger D.N., Kubes P. Nitric oxide as antiinflammatory agent. Methods in Enzymology. 269:1996;434-442.
11. Hernandez I., Cowley A.W., Lombard J.H., Greene A.S. Salt intake and angiotensin II alter microvessel density in the cremaster muscle of normal rats. Am. J. Physiol. 263:1992;H8664-H8667.
12. Jia L., Blantz R.C. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats. Eur. J. Pharmacol. 354:1998;33-41.
13. Jia L., Furchgott R.F. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther. 267:1993;371-378.
14. Jia L., Stamler J.S. Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier. Eur. J. Pharmacol. 366:1999;69-78.
15. Jia L., Bonaventura C., Bonaventura J., Stamler J.S. S-nitrosoheamoglubin: a dynamic activity of blood involved in vascular control. Nature. 380:1996;221-226.
16. Jia L., Yang X., Guo W. Physicochemistry, pharmacokinetics and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor. J. Pharm. Sci. 88:1999;981-986.
17. Kendrick K.M., Guevara-Guzman R., Zorrilla J., Hinton M.R., Broad K.D., Mimmack M., Ohkura S. Formation of olfactory memories mediated by nitric oxide. Nature. 388:1997;670-673.
18. Ku D.D., Zaleski J.K., Liu S., Brock T. Vascular endothelial growth factor induces EDRF-dependent relaxation of coronary arteries. Am. J. Physiol. 265:1993;H586-H592.
19. Lancaster J.R. Nitric oxide in cells. Am. Sci. 80:1992;248-259.
20. Le Noble F.A., Hekking J.W., Van Straaten H.W., Slaaf D.W., Struyker-Boudier H.A. Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo. Eur. J. Pharmacol. 195:1991;305-306.
21. Le Noble F.A., Schreurs N.H.J.S., Van Straaten H.W.M., Slaaf D.W., Smits J.F.M., Struyker-Boudier H.A. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am. J. Physiol. 264:1993;R460-R465.
22. Lin M.J., Yang X., Wang J., Jia B.J., Jia L. Inhibitory effects of S-nitrosocaptopril on vasomotor tone. Acta Pharmacol. Sin. 19:1998;485-488.
23. Loscalzo J., Smick D., Andon N., Cooke J. S-nitrosocaptopril: I. Molecular characterization and effects on the vasculature and on platelets. J. Pharmacol. Exp. Ther. 249:1989;726-729.
24. Mathews R.W., Kerr S. Biological activity of S-nitrosothiols: the role of nitric oxide. J. Pharmacol. Exp. Ther. 267:1993;1529-1537.
25. Myers P.R., Minor R.L., Guerra R. Jr., Bates J.N., Harrison D.G. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 345:1990;161-163.
26. Nikitovic D., Holmgrent S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J. Biol. Chem. 271:1996;19180-19185.
27. Nguyen M., Shing Y., Folkman J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 47:1994;31-40.
28. Pipili-Synetos E., Sakkoula E., Haralabopoulos G., Andriopoulou P., Peristeris P., Maragoudakis M.E. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br. J. Pharmacol. 111:1994;894-902.
29. Pipili-Synetos E., Papageorgiou A., Sakkoula E., Sotiropoulou G., Fotsis T., Karakiulakis G., Maragoudakis M.E. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br. J. Pharmacol. 116:1995;1829-1834.
30. Singh R.J., Hogg N., Joseph J., Kalyanaraman B. Mechanism of nitric oxide release from S-nitrosothiols. J. Biol. Chem. 271:1996;18596-18603.
31. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 98:1996;671-679.
32. Wink D.A., Cook J.A., Christodoulou D., Krishna M.C., Pacelli R., Kim S., DeGraff W., Gamson J., Vodovotz Y., Russo A., Mitchell J.B. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide Biol. Chem. 1:1997;88-94.